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BACKGROUND. Galectin-3 is a carbohydrate-binding protein whose level of expression has
been shown to be correlated with metastatic potential in a number of different tumor types.
The purpose of this investigation was to examine galectin-3 expression in several tumorigenic
and nontumorigenic prostate cell lines and prostate tissue samples.
METHODS. The expression of galectin-3 in cell lines and tissue samples was evaluated by
tissue immunohistochemistry and Western blot analysis.
RESULTS. Human cell lines PC-3M, PC-3, DU-145, PrEC-1, and MCF10A demonstrated the
presence of galectin-3. Galectin-3 was not detected in TSU-pr1 and LNCaP by Western blot
analysis. We furthered our studies by examining a series of human prostate tissue samples for
expression of galectin-3. Overall, approximately 60–70% of the normal tissue examined dem-
onstrated heterogenous expression of galectin-3. In stage II tumors, however, there was a
dramatic decrease in galectin-3 expression in both PIN and tumor sections, with only 10.5%
(2/19) of these samples expressing this protein. Stage III tumors also demonstrated a de-
creased expression of galectin-3, although this downregulation was not as dramatic, with 35%
of PIN samples and 52% of tumor tissue expressing galectin-3 (P < 0.01).
CONCLUSIONS. These data demonstrate that galectin-3 is downregulated in prostate can-
cer. The altered downregulation pattern of galectin-3 observed between tumor stages suggests
different roles for galectin-3 in the progression of prostate cancer. Prostate 44:118–123, 2000.
© 2000 Wiley-Liss, Inc.
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INTRODUCTION
The most devastating aspect of cancer is the ability
of tumor cells to disseminate from their primary site to
distant organ metastases. Cancer-related deaths are
most often the result of metastatic disease, rather than
the primary tumor. Carcinoma of the prostate is the
second leading cause of cancer-related deaths in males
in the United States. Projected estimates for 1999 in-
dicate that there will be approximately 179,300 newly
diagnosed prostate cancers, and that 37,000 men will
die from this disease [1]. More than half the number of
patients with prostate cancer already have metastases
at the time of diagnosis of their disease. Although
there has been much advancement and success in the
treatment of localized tumors, little has been found in
the way of treatment and prevention of metastatic can-
cer.
For a cancer cell to successfully leave the primary
tumor and establish itself in a new organ site requires
a complex cascade of events [2]. It involves the inva-
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sion of the primary tumor into the vasculature, the
release of tumor cells or tumor emboli into the circu-
lation, the arrest of these cells in distant organs, and
finally the development of these tumor cells into sec-
ondary neoplasms. If a tumor fails at any one of these
steps, metastasis does not occur.
One of the key steps in metastasis is the interaction
between the surface adhesion molecules on tumor em-
boli and receptor molecules on target organ endothe-
lium [3–6]. These surface adhesion molecules belong
to several families of proteins including the integrin,
cadherin, immunoglobin, laminin, and lectin families.
Galectin-3 (gal-3) is part of a growing family of carbo-
hydrate-binding proteins that fulfill two criteria: 1) af-
finity for b-galactosides; and 2) significant sequence
homology in the carbohydrate binding site [7]. Gal-3,
previously known as CBP-35, Mac-2, L-29, L-34, and
L-31, has a monomer Mr of approximately 30,000 and
consists of two distinct structural domains: an amino-
terminal domain containing a repetitive sequence rich
in leucine, tyrosine, and proline residues, and a car-
boxy terminal domain with a globular structure en-
compassing the carbohydrate binding site [7–14]. Gal-
3, through its interaction with specific ligands, is
involved in multiple biological processes, including
cell growth, differentiation, inflammation, transforma-
tion, metastasis, and adhesion [7–14]. Although the
precise role of gal-3 remains to be determined, several
studies have demonstrated that gal-3 is upregulated in
a variety of human cancers. For example, gal-3 expres-
sion was significantly higher in invasive colon cancers
as compared to colonic epithelium [15]. Studies have
also demonstrated that metastatic tissue expressed
higher levels of gal-3 than primary cancers [15]. Ex-
pression of gal-3 was upregulated in malignant thy-
roid neoplasms as compared to thyroid adenomas or
normal thyroid tissue, as well as tumors of the central
nervous system [16–18]. Alternatively, it has been pos-
tulated that gal-3 functions to bind cells to laminin in
the extracellular matrix, and loss of this expression
correlates with acquisition of an invasive phenotype.
Studies in endometrial, colon, and breast cancers dem-
onstrate decreased gal-3 expression as compared to
normal cells [19–21]. We previously reported that ga-
lectin-3 expression is found in prostate cancer cells,
and we postulated that gal-3 was involved in the pro-
gression of prostate cancer [22]. The purpose of this
study was to examine galectin-3 expression in normal
prostate tissue, prostate cancer tissue, and human
prostate cancer cell lines.
MATERIALS AND METHODS
Antibody Production
A polyclonal antibody to galectin-3 was previously
described [23]. Briefly, the galectin-3 gene was isolated
from the HT1080 human fibrosarcoma cDNA library
(lambda gt11 phage, Clontech, Palo Alto, CA), se-
quenced, and transferred to the EcoRI site of the bac-
terial expression vector, pET5b (Promega, Madison,
WI). Then, the protein product was extracted from the
bacteria cells, put over an asialofetuin column, and
eluted with lactose. The elutant was dialysed against
water and lyophilized. Afterward, the lyophilized
protein was sent to Zymed (San Francisco, CA) for
antibody production in rabbits.
Cell Culture
The MCF10A breast epithelial cell line was main-
tained in Dulbecco’s modified Eagle’s medium
(DMEM) and F-12 nutrient mixture (1:1; Gibco/BRL,
Gaithersburg, MD) supplemented with the following:
5% equine serum (Gibco/BRL), 1% antibiotic-
antimycotic solution (Sigma, St. Louis, MO), insulin
(10 mg/ml; Sigma), cortisol (1.4 × 10−6 M; Sigma), chol-
era enterotoxin (100 ng/ml; ICN Biomedicals, Cleve-
land, OH), and epidermal growth factor (20 ng/ml;
Gibco/BRL) [24]. The human prostate epithelial cell
line, PrEC-I, was obtained from Clonetics (San Diego,
CA) and immortalized in our laboratory, using the
SV-40 large T antigen as previously described [25].
This cell line was maintained in DMEM supplemented
with 10% fetal bovine serum (FBS; Gibco/BRL) and
1% antibiotic-antimycotic solution. The prostate cell
line TSU-PR1 was obtained from J. Isaacs (Johns Hop-
kins, Baltimore, MD) [26]. The human prostate cancer
cell lines PC3, DU145, and LNCaP were obtained from
the American Type Culture Collection (ATCC, Rock-
ville, MD) [27–30]. The human prostate cancer cell line
PC3 Bone, which metastasizes preferentially to bone
tissue, was obtained from Mark Stearns, Ph.D (Uni-
versity of Pennsylvania) [31]. TSU-PR1, DU-145, PC3
Bone, PC3, and LNCaP were maintained in RPMI-
1640 media containing 10% FBS and 1% antibiotic-
antimycotic solution.
Western Blot Analysis
Aliquots of whole-cell lysates were resolved by
electrophoresis on a 10% SDS-polyacrylamide gel, us-
ing standard procedures. After electrophoresis, the
gels were submerged in transfer buffer (192 mM gly-
cine and 0.25 mM Trizma base, pH 8.3) and allowed to
equilibrate for 30 min. Proteins were then transferred
to a Hybond ECL nitrocellulose membrane (Amer-
sham Life Sciences, Buckinghamshire, UK) for 1 hr at
4°C at 100 volts using a BioRad Mini Protean II Trans-
fer Unit (BioRad, Hercules, CA). For Western blotting,
the ECL Western Blotting Detection Kit was used
(Amersham Life Sciences). The detection system uses
a chemiluminescent reagent that is cleaved by horse-
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radish peroxidase (tethered to the secondary anti-
body) and produces a signal easily detected using
standard X-ray film. All reagents were obtained from
Amersham Life Sciences. After transfer, the mem-
brane was submerged in a 10% milk solution for 1 hr
to block any nonspecific binding. The membrane was
then washed quickly in PBS with 0.1% Tween 20
(PBST), followed by a 15-min wash in PBST and two
5-min washes in PBST. The membrane was incubated
for 1 hr at room temperature with a primary antibody
(rabbit anti-human galectin-3: 1 mg/ml in stock solu-
tion) at a final concentration of 300 mg/ml and washed
as stated above in PBST. The membrane was then in-
cubated for 30 min at room temperature with second-
ary antibody (sheep anti-rabbit Ig horseradish peroxi-
dase-linked whole antibody, Amersham Life Sciences;
0.125 mg/ml) and washed once in PBST for 15 min,
followed by four 5-min washes in PBST. After the final
wash, galectin-3 was detected using the ECL kit, fol-
lowing the manufacturer’s instructions. X-ray film
was placed over the membrane, and the film was ex-
posed for different time periods for optimum visual-
ization.
Prostate Tissue Immunohistochemistry
A modification of the biotin-avidin complex
method was used to determine the distribution of ga-
lectin-3 in 39 matched paraffinized normal and pros-
tate cancer tissue samples obtained from the Univer-
sity of Michigan Tissue Procurement Core. All
samples had been previously verified by a pathologist
(K.J.W.). Samples were first deparaffinized by twice
incubating in xylene for 5 min, ethanol for 3 min, and
90% ethanol for 3 min. Afterwards, slides were placed
in a 0.01 M PBS solution. Tissue section pairs were
incubated in an 8% goat serum solution in 0.01 M PBS
for 20 min at room temperature to block nonspecific
binding. The blocking solution was then removed, and
0.2 mg/ml of the gal-3 antibody in 0.01 M PBS were
added to one of the tissue sections for 2 hr at room
temperature. The other tissue section pair was incu-
bated in 0.01 M PBS only to detect any nonspecific
binding.
The gal-3 antibody solution was removed and tis-
sue sections were quickly rinsed twice with 0.01 M
PBS, and then washed twice for 5 min with 0.01 M
PBS. An anti-rabbit biotinylated secondary antibody
from the VECTASTAIN Elite Immunodetection Kit
(Vector Laboratories, Burlingame, CA) was added to
the tissue sections and allowed to incubate for 30 min,
followed by two quick washes and two 5-min washes
with 0.01 M PBS. Vectastain ABC complexing reagent
was then added to each tissue section and allowed to
incubate for 30 min, followed by two quick rinses and
two 5-min washes with 0.01 M PBS. Immunodetection
of galectin-3 on the tissue sections was visualized by
using the Vector peroxidase substrate kit (DAB kit).
Tissue sections were counterstained with hematoxylin
for 2 min, followed by incubation of tissue sections in
95% ethanol for 3 min twice, ethanol for 3 min twice,
and xylene for 3 min twice. Coverslips were mounted
using Permount (Fisher, Pittsburgh, PA).
Stained specimens were scored by two independent
observers on a scale ranging from 0–3, with 0 indicat-
ing a lack of stain and 3 indicating the presence of
intense staining. Observations took into account the
difference in staining between prostate intraepithelial
neoplasia (PIN), tumor, normal epithelial, and basal-
cell layers.
RESULTS
Expression of Galectin-3 in Prostate Cells
We first examined the pattern of expression of gal-3
in a series of nontumorigenic and tumorigenic pros-
tate cell lines by Western blot analysis (Fig. 1). Lysates
extracted from each cell line demonstrated the pres-
ence of a 29,000-kDa protein in the following cell
lines: MCF10A, PrEC-1, DU-145, PC-3, and PC-3M.
Despite numerous attempts, TSU-PR1 and LnCAP
cell lines did not demonstrate gal-3 expression (Fig.
1). There appears to be no significant difference in
Fig. 1. Expression of galectin-3 in human cell lines. Whole-cell lysates were extracted from described cultures and analyzed for galectin-3
expression according to the procedures outlined in Materials and Methods. The following human cell lines were analyzed for the 29,000-kDa
protein: MCF10A (positive control), PrEC-1, TSU, DU-145, LNCaP, PC3, and PC-3M (PC3 Bone).
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gal-3 protein expression when comparing protein ex-
pression in the nontumorigenic PREC-1 cell line to the
tumorigenic cell lines examined.
Expression of Galectin-3 in Human
Prostate Tissues
We next examined the tissue staining pattern of
normal, premalignant, and malignant prostate tissue
from 39 patients who had undergone radical prosta-
tectomy for stage II (19 patients) and III (20 patients)
prostate cancer. In stage II disease, 17/19 normal tis-
sue samples demonstrated positive staining of their
epithelial cells, and 8/19 samples demonstrated posi-
tive staining of their basal cells (Table I and Fig. 2).
Galectin-3 expression in atrophic glands was similar
to galectin-3 expression in normal glands (Fig. 2). The
expression of galectin-3 within the epithelial cells was
very heterogeneous, with 10/19 showing weak ex-
pression of galectin-3, 6/19 demonstrating moderate
expression, and 1/19 demonstrated strong expression
of galectin-3 throughout the sample. In patients with
stage III disease, epithelial cells and basal cells stained
positive for galectin-3 in 12/19 and 11/19 of normal
tissue samples, respectively. This pattern was similar
to the heterogeneous pattern demonstrating positive
staining observed in the stage II samples. Approxi-
mately 10% (2/19) of prostatic intraepithelial neopla-
sia (PIN) specimens in the patients with stage II pros-
tate cancer stained positive for gal-3, while 35% (7/19)
of specimens from stage III patients demonstrated ga-
lectin-3 expression. PIN appeared to only stain posi-
tively in patients’ samples with Gleason grade tumors
of 7 or less. Only 10.5% (2/19) of stage II tumors dem-
onstrated gal-3 staining, while 52% (10/19) of stage III
tumors stained positive (P < 0.01). Positive staining
was often focal and intense in tumors, suggesting that
subpopulations of cells were staining differently.
Staining in tumors did not correlate with Gleason
grade. Atrophic cells in all specimens stained in-
tensely.
DISCUSSION
It has been demonstrated that gal-3 has a variety of
functions in the cell, ranging from binding to the
nuclear matrix to acting as a substrate for matrix me-
talloproteinases. On the cell surface, gal-3 has been
demonstrated to bind laminin in the extracellular ma-
trix. Previous reports are contradictory, suggesting
that gal-3 may be upregulated or downregulated as a
cell requires a tumorigenic phentoype. Some reports
suggest that downregulation of gal-3 in conjunction
with dissolution of the basement membrane through
upregulation of metalloproteinases would allow tu-
mor cells to disseminate. Conversely, upregulation of
gal-3 in metastatic cells could allow greater adhesion
to target organ endothelial cells. In the present study,
we examined several prostate cell lines as well as hu-
man prostate tissue to determine the galectin-3 expres-
sion pattern in these samples. All cell lines, with the
exception of TSU-PR1 and LnCAP, demonstrated
gal-3 expression by Western blot analysis. Western
blot analysis failed to demonstrate the presence of ga-
lectin-3 in both LnCaP and TSU-PR1 cultures. These
results are consistent with recently reported results
examining expression of galectin-3 in human prostate
cell lines [32]. No change in in vitro expression of ga-
lectin-3 was observed by Western blot analysis of ly-
sates between the nontumorigenic line PREC-1 and
the tumorigenic lines examined.
Examination of the expression of galectin-3 in hu-
man prostate tissue, however, yielded interesting re-
sults. Prostate tissue samples from 39 patients contain-
ing a tumor tissue sample and matched control
samples were stained for galectin-3 expression. Over-
all, approximately 60–70% of the normal tissue exam-
ined demonstrated heterogenous expression of galec-
tin-3. It is conceivable that this heterogenous
expression of galectin-3 in normal tissue could be in-
fluenced by proximal tumor tissue. However, this no-
tion was not further explored in this study. In stage II
tumors, there was a dramatic decrease in galectin-3
expression in both PIN and tumor sections, with only
10% of these samples expressing this protein. Positive
staining was often focal and intense in tumors, sug-
gesting that subpopulations of the cells were staining
differently. Stage III tumors also demonstrated a de-
creased expression of galectin-3, although this de-
crease was not as dramatic, with 35% of PIN samples
and 50% of tumor tissue expressing galectin-3.
CONCLUSIONS
These observations are consistent with previous re-
ports demonstrating a decrease in galectin-3 expres-






Normal epithelial 89 (17/19) 62 (12/20)
Normal basal 45 (9/17) 55 (11/20)
PIN2 10.5 (2/19) 35 (7/20)
Tumor 10.5 (2/19) 50 (10/20)
a% is defined as percentage of samples which expressed galec-
tin-3 by immunocytochemical staining. Positive samples were
determined by two independent observers. Nineteen tissue
samples from stage II patients and 20 tissue samples from stage
III patients were analyzed.
bPIN, prostatic intraepithelial neoplasia.
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sion in endometrial, breast, and ovarian cancers
[19,20,33]. Although this is controversial, other inves-
tigations have shown an increase in galectin-3 in ma-
lignant progression [15,21]. Other reports also demon-
strate that increased expression of galectin-3 is
associated with high metastatic potential [15–18]. Our
results, combined with those previously reported,
suggest that the role of galectin-3 in tumorigenesis
may be dependent on cell type. Furthermore, our data
support the notion that galectin-3 may play a different
role in tumor progression depending on tumor stage.
Our data do not clearly indicate that a dramatic de-
crease is observed in tumors of all stages, as those of
higher stage demonstrated only slight, albeit statisti-
cally significant (P < 0.01) decreased expression. This
phenomenon may also explain the lack of expression
of galectin-3 observed in LnCaP and TSU-Prl cultures.
Alternatively, this lack of expression in LnCaP and
TSU-Pr1 cultures or the expression of galectin-3 in the
other cell lines examined could be attributed to cul-
tural artifacts. Further studies are warranted to exam-
ine the expression pattern of galectin-3 in more tumor
specimens to determine the role of galectin-3 expres-
sion in prostate cancer progression.
Fig. 2. Expression of galectin-3 in human prostate tissue. Samples were subjected to immunohistochemistry, using a polyclonal antibody
to galectin-3 as described in Materials and Methods. Pictures were taken at a magnification of ×10. Staining of cells was heterogeneous;
examples are given here of (A) basal cells, (B) epithelial cells, (C) atrophic, (D) PIN, (E) focal tumor, and (F) patchy tumor.
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